Bay Area's Global Blood Therapeutics Terminates Lung Disease Program Post author:Sam Post published:October 22, 2017 Post category:BioPharma The company is shuttering its GBT440 program to treat idiopathic pulmonary fibrosis (IPF). Source: BioSpace You Might Also Like How Artificial Life Spawned A Billion-Dollar Industry April 5, 2017 INC Research Schedules Fourth Quarter And Year End 2016 Earnings Call For Tuesday, February 28, 2017 February 6, 2017 3 Biotechs With Critical Product Launches in 2018 December 10, 2017
INC Research Schedules Fourth Quarter And Year End 2016 Earnings Call For Tuesday, February 28, 2017 February 6, 2017